SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022
Authors:
Open Access
- 5 May 2022
- journal article
- research article
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 27 (18) , 2200178-24
Abstract
Background: Omicron subvariant BA.2 circulation is rapidly increasing globally. Aim: We evaluated the neutralising antibody response from vaccination or prior SARS-CoV-2 infection against symptomatic infection by BA.2 or other variants. Methods: Using 50% plaque reduction neutralisation tests (PRNT50), we assessed neutralising antibody titres to BA.2, wild type (WT) SARS-CoV-2 and other variants in Comirnaty or CoronaVac vaccinees, with or without prior WT-SARS-CoV-2 infection. Titres were also measured for non-vaccinees convalescing from a WT-SARS-CoV-2 infection. Neutralising antibodies in BA.2 and BA.1 breakthrough infections and in BA.2 infections affecting non-vaccinees were additionally studied. Results: In vaccinees or prior WT-SARS-CoV-2-infected people, BA.2 and BA.1 PRNT50 titres were comparable but significantly (p < 10 − 5) lower than WT. In each group of 20 vaccinees with (i) three-doses of Comirnaty, (ii) two CoronaVac followed by one Comirnaty dose, or (iii) one dose of either vaccine after a WT-SARS-CoV-2 infection, ≥ 19 individuals developed detectable (PRNT50 titre ≥ 10) antibodies to BA.2, while only 15 of 20 vaccinated with three doses of CoronaVac did. Comirnaty vaccination elicited higher titres to BA.2 than CoronaVac. In people convalescing from a WT-SARS-CoV-2 infection, a single vaccine dose induced higher BA.2 titres than three Comirnaty (p = 0.02) or CoronaVac (p = 0.00001) doses in infection-naïve individuals. BA.2 infections in previously uninfected and unvaccinated individuals elicited low (PRNT50 titre ≤ 80) responses with little cross-neutralisation of other variants. However, vaccinees with BA.1 or BA.2 breakthrough infections had broad cross-neutralising antibodies to WT viruses, and BA.1, BA.2, Beta and Delta variants. Conclusions: Existing vaccines can be of help against the BA.2 subvariant.Keywords
This publication has 23 references indexed in Scilit:
- Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 MonthsNew England Journal of Medicine, 2021
- Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID‐19 vaccines in Hong KongRespirology, 2021
- Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysisThe Lancet Microbe, 2021
- Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2Nature, 2021
- Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protectioneClinicalMedicine, 2021
- Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent mannerCell Host & Microbe, 2021
- SARS-CoV-2 variants, spike mutations and immune escapeNature Reviews Microbiology, 2021
- An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodiesCell, 2021
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionNature Medicine, 2021
- Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cellsProceedings of the National Academy of Sciences of the United States of America, 2020